SMA is an inherited neurological disorder that results in progressive muscle wasting, impacting a person’s ability to move and even breathe. Although this disease is rare, with a U.S. incidence rate of 1 in 10,000 live births, it is the leading genetic cause of death in infants, and prior to Spinraza’s approval it lacked any form of effective pharmaceutical intervention.